异动解读｜中国生物制药盘中上涨3.83%，贝莫苏拜单抗联合安罗替尼肺鳞癌新适应症获批

行情直击08-10

8月10日，中国生物制药盘中上涨3.83%，报5.23港元，成交额3842.54万港元。

消息面上，公司8月7日公告，旗下正大天晴自研的贝莫苏拜单抗注射液联合化疗序贯联合安罗替尼胶囊获NMPA批准上市，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌，为安罗替尼第12个获批适应症、贝莫苏拜单抗第6个获批适应症。此外，公司近期管线密集兑现：8月6日第二代氟比洛芬贴剂获批上市，面向超2亿慢性疼痛患者市场；8月4日BCL-2抑制剂TQB3909片NDA获CDE受理并进入优先审评；8月3日ADC新药TQB2102第三次获突破性治疗认定。多项催化叠加，驱动市场情绪走强。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1117797293?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-10 09:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1117797293","market":"hk","top_or_hot":-1,"title":"异动解读｜中国生物制药盘中上涨3.83%，贝莫苏拜单抗联合安罗替尼肺鳞癌新适应症获批","media":"行情直击","content":"<p><p>8月10日，中国生物制药盘中上涨3.83%，报5.23港元，成交额3842.54万港元。</p><p>消息面上，公司8月7日公告，旗下正大天晴自研的贝莫苏拜单抗注射液联合化疗序贯联合安罗替尼胶囊获NMPA批准上市，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌，为安罗替尼第12个获批适应症、贝莫苏拜单抗第6个获批适应症。此外，公司近期管线密集兑现：8月6日第二代氟比洛芬贴剂获批上市，面向超2亿慢性疼痛患者市场；8月4日BCL-2抑制剂TQB3909片NDA获CDE受理并进入优先审评；8月3日ADC新药TQB2102第三次获突破性治疗认定。多项催化叠加，驱动市场情绪走强。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜中国生物制药盘中上涨3.83%，贝莫苏拜单抗联合安罗替尼肺鳞癌新适应症获批</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜中国生物制药盘中上涨3.83%，贝莫苏拜单抗联合安罗替尼肺鳞癌新适应症获批\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-10 09:33 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月10日，中国生物制药盘中上涨3.83%，报5.23港元，成交额3842.54万港元。消息面上，公司8月7日公告，旗下正大天晴自研的贝莫苏拜单抗注射液联合化疗序贯联合安罗替尼胶囊获NMPA批准上市，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌，为安罗替尼第12个获批适应症、贝莫苏拜单抗第6个获批适应症。此外，公司近期管线密集兑现：8月6日第二代氟比洛芬贴剂获批上市，面向超2亿慢性疼痛患者市场；8...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01177","symbol_name":"中国生物制药","start_time":0,"source_url":"","article_id":"1117797293","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1117797293","pubTimestamp":1786325607,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月10日，中国生物制药盘中上涨3.83%，报5.23港元，成交额3842.54万港元。消息面上，公司8月7日公告，旗下正大天晴自研的贝莫苏拜单抗注射液联合化疗序贯联合安罗替尼胶囊获NMPA批准上市，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌，为安罗替尼第12个获批适应症、贝莫苏拜单抗第6个获批适应症。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"01177":"中国生物制药"},"translate_title":"Interpretation of the change | China Biopharmaceuticals rose 3.83% in the intraday session, and the new indication of bemosubizumab combined with anlotinib for lung squamous cell carcinoma was approved","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01177":1},"content_text":"8月10日，中国生物制药盘中上涨3.83%，报5.23港元，成交额3842.54万港元。消息面上，公司8月7日公告，旗下正大天晴自研的贝莫苏拜单抗注射液联合化疗序贯联合安罗替尼胶囊获NMPA批准上市，用于一线治疗局部晚期或转移性鳞状非小细胞肺癌，为安罗替尼第12个获批适应症、贝莫苏拜单抗第6个获批适应症。此外，公司近期管线密集兑现：8月6日第二代氟比洛芬贴剂获批上市，面向超2亿慢性疼痛患者市场；8月4日BCL-2抑制剂TQB3909片NDA获CDE受理并进入优先审评；8月3日ADC新药TQB2102第三次获突破性治疗认定。多项催化叠加，驱动市场情绪走强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1117797293","isCrawlerRequest":true}